<DOC>
	<DOCNO>NCT01201915</DOCNO>
	<brief_summary>This 3-cohort , open-label study vismodegib ( GDC-0449 ) new ( non-recurrent ) operable basal cell carcinoma nodular subtype .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Vismodegib ( GDC-0449 ) Operable Basal Cell Carcinoma</brief_title>
	<detailed_description>For Cohort 1 , response treatment determine end 12 week treatment . For Cohort 2 , response treatment determine 12 week treatment 24 week observation . For Cohort 3 , response treatment determine intermittent dose 20-week period , consist initial 8-week treatment period , follow 4-week drug holiday period , follow second 8-week treatment period .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Confirmed new ( recurrent previously treat ) nodular basal cell carcinoma ( BCC ) 1 listed anatomical site , must biopsy confirm study site . Willingness consent biopsy lesion . Willingness delay excision target tumor site time mandate protocol , unless evidence disease progression lack drug tolerability . Adequate hematopoietic capacity . Adequate hepatic function . For woman childbearing potential , agreement use 2 acceptable form birth control ( include one barrier method ) study 7 month discontinuation study drug . For men female partner childbearing potential , agreement use male condom ( spermicide ) advise female partner use additional acceptable method birth control study 2 month discontinuation study drug . Agreement donate blood/blood product study 7 month discontinue study drug . Agreement donate sperm semen treatment 2 month last dose vismodegib . Prior treatment vismodegib Hedgehog pathway inhibitor . Inability unwillingness swallow capsule . Pregnancy lactation . BCC clinical histological pattern nodular BCC . Patients know Gorlin 's syndrome ( basal cell nevus syndrome ) clinical suspicion Gorlin 's syndrome . Recent ( ie , within past 28 day ) , current , planned participation another experimental drug study . Use exclude medication therapy within 21 day study entry . History malignancy within 3 year first day treatment ( Day 1 ) , except tumor negligible risk metastasis , nonmelanoma skin cancer ( BCC , squamous cell cancer ) , ductal carcinoma situ breast , carcinoma situ cervix . Uncontrolled medical illness . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication . Any medical psychological illness condition prevent adequate consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>